Author Archive: David Thomas, CFA

David Thomas, CFA

David is currently Director of Industry Research and Analysis at BIO in Washington, DC. In this role, he is responsible for financial statistics and analysis of the biotechnology sector and contributes to BIO’s policy activities as well as programming for BIO’s investor conferences. Prior to joining BIO, he was a research scientist at the J. Craig Venter Institute working on the “synthetic cell” team led by Nobel Laureate Hamilton Smith. Before his role in synthetic biology, David worked as a scientist in drug discovery at Amgen, Millennium, and Novartis. His scientific expertise is in protein engineering, enzymology, and synthetic biology. David has earned the Chartered Financial Analyst (CFA) designation and holds a master’s degree in biochemistry.

Latest Posts

Choose Your Own Adventure – The Private Biotech Crossroads

It is a known fact within the private company biopharma universe that the days of certainty for public exits, subsequent private financings, and even pharma licensing deals are over. IPOs have been out of favor for five years, venture firms are turning away from the sector, and fewer licensing deals are being cut. What is less understood about this uncertain environment is how it has forced management and their venture backers, to not only rethink Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Kinase Drug Development – Making Progress

The kinase inhibition field has had plenty of ups and downs and over the last decade, but when we take a look at recent approvals and NDA filings there seems to be a strengthening of the field. There are now 16 kinase inhibitors that have been approved and five seeking regulatory approval in the next few months. The last two years in particular has been a boom for the KIs, with seven approvals, three of which target Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

How does the NBI perform in the last quarter of the year?

YTD-10-08-2012

Does the NASDAQ Biotech Index (NBI) outperform the broader market in the last three months of the year, or underperform? The NBI tends to be up in the 4th quarter, but a lot of that has to do with the overall market, not the biotechs. Here are the returns for the last quarter of the year for the last 20 years: (source: Factset) When looking directly at overall performance, biotech and the broader market have had good Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Is the early-stage IPO making a comeback?

Yesterday was the NASDAQ debut for preclinical-stage biotech Regulus (RGLS). The microRNA platform company is working in multiple therapeutic areas and planning to reach the clinic in 2014. Since the start of the 2009 post-market crash window for biotech IPOs, there have been only two preclinical biotech companies to make it to the public stage. Back in January, we saw Verastem (VSTM), at only 1.5 years of age, make it to the NASDAQ and raise Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

Indices, IPOs, Approvals – YTD Update Aug 14th, 2012

We are now more than eight months into the year and biotech indices have maintained their outperformance, squeezed out a modest size IPO class, and delivered double digit novel FDA approvals. 1. Indices. The Nasdaq Biotech Index (NBI) is up 27% Year to Date (YTD) as of last Friday. It was up nearly 20% by the end of the 1st quarter, consolidated during the 2nd quarter, and has participated in the summer rally to tack on another 7%. Here Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,